Late on Friday the FDA came through with an approval for Actelion’s pulmonary arterial hypertension (PAH) drug Opsumit (macitentan), its next-gen successor to the franchise drug Tracleer. And on Monday the Swiss company’s shares shot up 7% on the news. The approval comes as no great surprise. The company ($ATLN) had been steadily doing the […]
↧